Men's Health News

RSS

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.

9 Feb 2010

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

9 Feb 2010

Repros Therapeutics submits Androxal revised indication statement to the FDA

Repros Therapeutics Inc. today announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA’s Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state.

8 Feb 2010

Non-invasive MR Spectroscopy to determine ability to be fathers

Men with no sperm in their ejaculate—a condition known as azoospermia—may no longer need invasive procedures to determine if they have sperm in their testes according to a new study published in Human Reproduction.

5 Feb 2010

Ipsen launches Decapeptyl LP 22.5 mg in France

Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

4 Feb 2010

Older male Italian immigrants more prone to depression

Older male Italian immigrants are almost twice as likely to suffer from depression as their Australian-born counterparts, researchers from the University of Sydney's School of Public Health have found.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Men welcome male contraceptive pill currently undergoing trials

Would you trust men to take a 'male pill'? That's the question posed to 380 people in North East England by a team from Teesside University which questioned people about the male contraceptive pill currently undergoing trials.

28 Jan 2010

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).

27 Jan 2010

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Researchers at Moores Cancer Center at the University of California, San Diego and colleagues have found that prostate cancer treatments varied significantly between county hospitals and private providers. Patients treated in county hospitals are more likely to undergo surgery while patients treated in private facilities tend to receive radiation or hormone therapy. These findings were published online by the journal Cancer on January 25.

25 Jan 2010

Smoking and high blood pressure increase risk of abdominal aortic aneurysm in men over 60

Men ages 65 and older who have ever smoked should have a one-time, say cardiologists at UT Southwestern Medical Center. Men age 60 and older with a family history of abdominal aortic aneurysm should also consider screening. High blood pressure and a history of smoking can increase your chances of having an abdominal aortic aneurysm.

23 Jan 2010

Over 44% of internet Viagra is counterfeit

Research by UK, Swedish and American researchers shows that taking internet drugs can kill and bypassing health systems can leave life-threatening problems undiagnosed. It's estimated that 90% of counterfeit drugs are sold on the internet, 44% of internet Viagra is fake, the global sale of counterfeit drugs will reach $75 billion this year and EU seizures have risen dramatically. Counterfeit drug deaths include men who took fake erectile dysfunction drugs, pregnant women injected with fake iron for anaemia and children who took paracetamol syrup contaminated with antifreeze.

20 Jan 2010

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.

20 Jan 2010

Erectile dysfunction can be strongly related to the development of CVD

In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).

20 Jan 2010

Bone marrow transplantation survivors can father children: new study says

Men who were previously deemed sterile due to aggressive cancer treatments may still be able to biologically father children according to a new study published in the journal, Bone Marrow Transplantation.

18 Jan 2010

Androgen replacement therapy may ward off heart damage, says study

A man's male hormones may ward off heart damage by helping vessels around the heart regenerate, suggest Australian researchers in a report posted January 13 in the Journal of Experimental Medicine (www.jem.org).

18 Jan 2010

European trial casts doubt over the viability of prostate cancer screening

A large European trial has cast doubt over the viability of prostate cancer screening, concluding that one in eight men receive a positive test result when they do not have the disease.

13 Jan 2010

Researchers identify genetic variant linked with the risk of prostate cancer

Researchers at Wake Forest University Baptist Medical Center and colleagues have identified the first genetic variant associated with aggressive prostate cancer, proving the concept that genetic information may one day be used in combination with other factors to guide treatment decisions.

12 Jan 2010

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.

11 Jan 2010

Men's Health News

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Repros Therapeutics submits Androxal revised indication statement to the FDA

Non-invasive MR Spectroscopy to determine ability to be fathers

Ipsen launches Decapeptyl LP 22.5 mg in France

Older male Italian immigrants more prone to depression

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Men welcome male contraceptive pill currently undergoing trials

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Smoking and high blood pressure increase risk of abdominal aortic aneurysm in men over 60

Over 44% of internet Viagra is counterfeit

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

Erectile dysfunction can be strongly related to the development of CVD

Bone marrow transplantation survivors can father children: new study says

Androgen replacement therapy may ward off heart damage, says study

European trial casts doubt over the viability of prostate cancer screening

Researchers identify genetic variant linked with the risk of prostate cancer

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News